Biocon: Taking a Crack at the Global Biosimilar Market

Soma Dey

South Asian Journal of Business and Management Cases, 2019, vol. 8, issue 1, 100-110

Abstract: India’s first biotechnology company, Biocon, has developed into a fully integrated biotechnology company with an impressive portfolio of small molecule generic drugs as well as new research initiatives. From 2007, Biocon has started paying attention to the new market for biologics and biosimilars. The current global biosimilar market is worth US$3.3 billion with an expected growth rate of 25 per cent. Over a decade of research, strategic collaborations and acquisition of strategic assets have enabled Biocon to become the leading biosimilar manufacturer in India. However, the biosimilar market remains a difficult market globally. The complex manufacturing process of biosimilars makes it harder to manufacture quality biosimilars. The regulatory environments in different countries are a major challenge. Also, various other large global pharmaceutical companies are actively seeking access to this market, thereby increasing competition for all. Biocon has to face all these issues as it goes ahead with an outward-looking plan of expanding its biosimilar and biologics portfolio.

Keywords: Biocon; biosimilar; India; pharmaceutical; regulation (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/2277977918803186 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:sajbmc:v:8:y:2019:i:1:p:100-110

DOI: 10.1177/2277977918803186

Access Statistics for this article

More articles in South Asian Journal of Business and Management Cases
Bibliographic data for series maintained by SAGE Publications ().